Intracameral sustained release therapeutic agent implants
Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.
1. A method for treating glaucoma in an eye comprising the steps of:
providing at least two biodegradable sustained release implants containing at least one therapeutic agent;
implanting the at least two biodegradable sustained release implants into the anterior chamber of the eye; and
treating the glaucoma,
wherein each of the at least two biodegradable sustained release implants releases about 100 ng per day to about 900 ng per day of the at least one therapeutic agent over the lifetime of the implant, and wherein the at least two biodegradable sustained release implants each comprise about 5% to about 40% of the least one therapeutic agent, about 10% to about 60% R203S, which is a poly(D,L-lactide) having an inherent viscosity of about 0.25 to about 0.35 dl/g, about 5% to about 20% R202H, which is a poly(D,L-lactide) having an inherent viscosity of about 0.16 to about 0.24 dl/g, about 5% to about 40% RG752S, which is a poly(D,L-lactide-co-glycolide) having a D,L-lactide:glycolide molar ratio of about 73:27 to about 77:23 and an inherent viscosity of about 0.16 to about 0.24 dl/g, and about 5% to about 15% polyethylene glycol (PEG).
2. The method according to claim 1 , wherein the at least one therapeutic agent is selected from the group consisting of latanoprost, bimatoprost and travoprost.
3. The method according to claim 1 , wherein the at least one therapeutic agent is a prostamide.
4. The method according to claim 1 , wherein the at least one therapeutic agent is bimatoprost.
5. The method according to claim 1 , wherein the at least two biodegradable sustained release implants each comprise about 20% bimatoprost, about 45% R203S, about 10% R202H, about 20% RG752S, and about 5% polyethylene glycol (PEG).
6. The method according to claim 1 , wherein each of the at least two biodegradable sustained release implants is produced by an extrusion method.